Home > Insider Trading > Filing (0000899243-19-027225)

Filing Details

Accession Number:: 0000899243-19-027225
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2019-11-13 19:07:06
Reporting Period:: 2019-11-11

Accepted Time:: 2019-11-13 19:07:06
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1785173	89Bio Inc.	ETNB	Pharmaceutical Preparations (2834)	831114349

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1792060	Anat Naschitz	C/O 89Bio, Inc. 535 Mission Street, 14Th Floor San Francisco CA 94105		Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2019-11-11	418,750	$16.00	724,363	No	4	P	Indirect	See footnotes
Common Stock	Acquisiton	2019-11-11	418,750	$16.00	724,363	No	4	P	Indirect	See footnotes
Common Stock	Acquisiton	2019-11-13	1,277,858	$0.00	2,002,221	No	4	C	Indirect	See footnotes
Common Stock	Acquisiton	2019-11-13	1,277,858	$0.00	2,002,221	No	4	C	Indirect	See footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See footnotes
No	4	P	Indirect	See footnotes
No	4	C	Indirect	See footnotes
No	4	C	Indirect	See footnotes

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2019-11-13	7,944,444	$0.00	1,277,858	$0.00
Common Stock	Series A Preferred Stock	Disposition	2019-11-13	7,944,444	$0.00	1,277,858	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
0			No	4	C	Indirect

Footnotes

On November 11, 2019, OrbiMed Private Investments VI, LP ("OPI VI") purchased 418,750 shares of the Issuer's common stock and OrbiMed Israel Partners II, L.P. ("OIP II") purchased 418,750 shares of the Issuer's common stock at a price of $16.00 per share in the Issuer's initial public offering.
The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-6.217 immediately prior the closing of the Issuer's initial public offering on November 13, 2019 and had no expiration date.
These securities are held of record by OPI VI. OrbiMed Capital GP VI LLC ("OrbiMed GP VI") is the general partner of OPI VI and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of OrbiMed GP VI. By virtue of such relationships, OrbiMed GP VI and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI VI and as a result may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein.
These securities are held of record by OIP II. OrbiMed Israel GP II, L.P. ("Israel GP II") is the general partner of OIP II, and OrbiMed Advisors Israel II Limited ("Advisors Israel II") is the general partner of Israel GP II. Advisors Israel II and Israel GP II may be deemed to have shared voting and investment power over all of the shares of common stock held by OIP II, and both Advisors Israel II and Israel GP II may be deemed to directly or indirectly, including by reason of their mutual affiliation, to be the beneficial owners of the shares held by OIP II. Advisors Israel II exercises this investment power through an investment committee comprised of Carl L. Gordon, Jonathan T. Silverstein, Nissim Darvish, Anat Naschitz, and Erez Chimovits, each of whom disclaims beneficial ownership of the shares held by OIP II. The Reporting Person disclaims beneficial ownership of the shares held by OIP II, except to the extent of her pecuniary interest therein, if any.
The Reporting Person is an Employee of Advisors Israel II. Each of OrbiMed GP VI, OrbiMed Advisors, Israel GP II, Advisors Israel II, and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or her pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any such entity or person, including the Reporting Person, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.